HDAC6 and atypical Rett syndrome: HDACs have been suggested as therapeutic targets for Rett Syndrome (Shukla and Tekwani, 2020) and HDAC6 inhibition has been linked to improved BDNF trafficking in a Rett mouse model (Xu et al., 2014).